A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

This Phase 2 study is testing ivonescimab — a new drug that targets both cancer blood vessel growth and the immune checkpoint protein PD-1 — in people with advanced or spreading salivary gland cancer that cannot be surgically removed. **You may be eligible if...** - You are 18 or older - You have been confirmed by biopsy to have salivary gland cancer that has spread, returned, or cannot be surgically removed - You have measurable cancer on imaging - Your cancer has shown progression or worsening in the past 12 months - Your blood counts, kidney, and liver function are adequate - You have not previously received an oral VEGF receptor blocker or anti-PD-1 immunotherapy **You may NOT be eligible if...** - You have active or uncontrolled brain cancer spread - You are pregnant or breastfeeding - You have another active cancer requiring treatment - You have significant autoimmune disease requiring long-term steroid use - You have had a major surgery in the past 4 weeks - You have significant bleeding problems or uncontrolled high blood pressure - You have had a recent heart attack, stroke, or serious cardiac event in the past 12 months Talk to your doctor to see if this trial is right for you.